NJ-IEEE
15.9.2021 16:37:03 CEST | Business Wire | Press release
IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Standards Association (IEEE SA) today announced the launch of IEEE 7000™-2021 - IEEE Standard Model Process for Addressing Ethical Concerns During System Design that provides a clear methodology to analyze human and social values relevant for an ethical system engineering effort.
IEEE 7000-2021 is recommended for use by organizations that seek to apply broader ethical value criteria and minimize risk, thereby helping to strengthen relationships with their end users and customers. Organizations may apply this first of its kind standard across multiple levels including concept exploration, system requirements definition, or development of new or revised products or services.
“Engineers, their managers, and other stakeholders benefit from well-defined processes for considering ethical issues along with the usual concerns of system performance and functionality early in the system life cycle,” said Konstantinos Karachalios, Managing Director of IEEE SA. “End users can be unaware of the ethical considerations regarding the products and services they use; this is why IEEE supported the launch of the IEEE 7000 series of standards including this standard that also complements our Ethics Certification Program for Autonomous and Intelligent Systems (ECPAIS) certification criteria offering. It is only by rigorously prioritizing ethical concerns at the outset of design that manufacturers, engineers, and technologists can responsibly align products and services with results honoring the contextual values of customers, citizens, and society at large.”
This standard provides:
- a system engineering standard approach integrating human and social values into traditional systems engineering and design.
- processes for engineers to translate stakeholder values and ethical considerations into system requirements and design practices.
- a systematic, transparent, and traceable approach to address ethically-oriented regulatory obligations in the design of autonomous intelligent systems.
“Value-based Engineering (VbE), a methodology providing ways to elicit, conceptualize, prioritize and respect end user values in system design, is at the heart of IEEE 7000-2021 and provides companies with a highly practical approach to master the values based challenges of their digital transformation,” said Dr. Sarah Spiekermann, Chair of The Institute for Information Systems & Society at Vienna University of Economics and Business (WU Vienna) and Vice-Chair of IEEE 7000-2021. "IEEE 7000-2021 test users identified ten issues per person involved in the project, demonstrating that the utilization of value-based Engineering can lead to fewer project risks and exponential innovation. This is a massive improvement relative to current technical roadmap processes."
A key part of digital transformation provided by IEEE 7000-2021 comes in addressing risk. Where traditional evaluations of technological risk may focus largely on areas of physical harm, the VbE methodology provides a broader lens to consider also potential value harms associated with product or systems design. This makes the standard unique and deeply important in terms of ease of adoption of applied ethics methodologies in emerging technologies such as AI.
The use of this standard could help organizations better earn and keep the trust of end-users and stakeholders by directly addressing ethical concerns upfront, leading to greater market acceptance of their products, services, or systems.
For more information, to purchase, or to view a read-only version of the IEEE 7000-2021 Standard, click here .
To learn more about IEEE SA or about any of its many market-driven initiatives, visit us on Facebook , follow us on Twitter , connect with us on LinkedIn , or on the Beyond Standards Blog .
About the IEEE Standards Association
IEEE Standards Association (IEEE SA) is a collaborative organization where innovators raise the world's standards for technology. IEEE SA provides a globally open, consensus-building environment and platform that empowers people to work together in the development of leading-edge, market-relevant technology standards, and industry solutions shaping a better, safer, and sustainable world. For more information, visit https://standards.ieee.org .
About IEEE
IEEE is the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more at https://www.ieee.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005012/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
